Day: December 29, 2021

29 December 2021, 14:15 CET ArcelorMittal (the ‘Company’) today announces that it has completed the fifth share buyback program announced on 17 November 2021 under the authorization given by the annual general meeting of shareholders of 8 June 2021 (the ‘2021 AGM Authorization’). By market close on 28 December 2021, ArcelorMittal had repurchased 34,080,049 shares for a total value of €885,729,034.96 (equivalent to US$999,999,819.63) at an approximate average price per share of €25.99. All details are available on the Company’s website at: https://corporate.arcelormittal.com/investors/equity-investors/share-buyback-program. ENDS About ArcelorMittal ArcelorMittal is the world’s leading steel and mining company, with a presence in 60 countries and primary steelmaking facilities in 17 countries. In 2020, ArcelorMittal had revenues...

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Seer’s management is scheduled to present and participate in a Q&A session on Monday, January 10 at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference. About Seer Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution...

EHang Launches 5G Intelligent Air Mobility Experience Center as AAV Operation Spot in GuangzhouCeremony of the 5G Intelligent Air Mobility Experience Center launchEHang Launches 5G Intelligent Air Mobility Experience Center as AAV Operation Spot in GuangzhouThe EH216 AAV’s passenger-carrying flight demo at the 5G Intelligent Air Mobility Experience CenterEHang Launches 5G Intelligent Air Mobility Experience Center as AAV Operation Spot in GuangzhouThe EH216 AAV’s passenger-carrying flight demo at the 5G Intelligent Air Mobility Experience CenterThe 5G Intelligent Air Mobility Experience Center launches in Guangzhou as a new operation spot under EHang’s 100 Air Mobility Routes Initiative. EHang and Guangzhou Development District Communications Investment Group establish a joint venture...

Ewing sarcoma arm advances to second lead-in safety dosing cohort in Sarcoma trial evaluating seclidemstat in combination with chemotherapy agents in patients with relapsed/refractory Ewing sarcoma and as a single-agent therapy in FET-rearranged sarcomas HOUSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, today announced an important dosing milestone in the Phase 1/2 Sarcoma clinical trial evaluating seclidemstat as a treatment for Ewing sarcoma and other FET-rearranged sarcomas. The trial’s Ewing sarcoma patient arm investigating seclidemstat in combination with chemotherapy agents topotecan and cyclophosphamide (TC) has advanced to the second lead-in safety cohort treating...

BATON ROUGE, La., Dec. 29, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, at 3:45 p.m. EST. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. About Amedisys: Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether...

Ji’an, Jiangxi, China, Dec. 29, 2021 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into a strategic cooperation agreement (the “Agreement”) with Jinggangshan University (“JGSU”), a public university located in Ji’an City of Jiangxi Province, for a study on the chemical constituents of Liparis Odorata, a traditional Chinese medicine, for the treatment of hyperlipidemia. Under the Agreement, JGSU agrees to conduct the aforementioned studies and provide scientific research results to the Company, and report to the Company upon completion within 24 months from the date of the Agreement. Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are excited to collaborate with JGSU...

HENDERSON, Nev., Dec. 29, 2021 (GLOBE NEWSWIRE) — P3 Health Partners Inc. (NASDAQ: PIII, or “P3”), a patient-centered and physician-led population health management company, today announced that its Chief Executive Officer, Dr. Sherif Abdou, and members of the P3 management team will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 5:15 p.m. (ET) / 2:15 p.m. (PT). The appearance will be webcast live and can be accessed in the Events & Presentations section of the P3 investor website. A replay will be available on the Company’s website following the event. To receive additional information, request an invitation or to schedule a one-on-one meeting, please contact your J.P. Morgan representative or the Company’s investor relations team at PIII@gatewayir.com. About P3 Health...

HOLLYWOOD, Fla., Dec. 29, 2021 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of compliance, technology, engineering, and environmental consulting solutions, announced today that it has been named the title sponsor for the Korn Ferry Tour’s Chicagoland area tournament hosted by the Western Golf Association. The NV5 Invitational will be played at The Glen Club in Glenview, IL from May 26-29, 2022 and will include a full field of 156 players competing for a $750,000 purse. All proceeds will support the Evans Scholars Foundation which provides full tuition and housing scholarships to caddies who demonstrate academic excellence and financial need. 2022 NV5 Investor DayNV5 will host an investor day at The Glen Club on Thursday, May 26, 2022 during the NV5 Invitational. NV5 will present its growth...